Browse > Article
http://dx.doi.org/10.5352/JLS.2010.20.10.1544

Relationship between Moxifloxacin Resistance Pheno- and Genotype of Moxifloxacin-Resistant Mycoplasma hominis Obtained in vitro  

Park, In-Dal (Department of Microbiology Kosin University College of Medicine)
Choi, Myung-Won (Research Institute for Antimicrobial Resistance)
Publication Information
Journal of Life Science / v.20, no.10, 2010 , pp. 1544-1548 More about this Journal
Abstract
Moxifloxacin (MF) - resistant mutants of Mycoplasma hominis (M. hominis) were generated by stepwise selection in increasing concentrations of MF, and six strains of MF resistant M. hominis mutants - M1, M4, M8, M16, M32, and M64 - in which MICs of MF were 0.5, 4, 8, 16, 32, 64 ${\mu}g$/ml, respectively, were generated. Compared to the sequence of M. hominis PG21, all mutants harbored amino acid substitutions of Arg-163 Thr in GyrA, and Pro-445 Gln in ParE. While the concentrations were getting higher, an additional amino acid substitution was found at Ser-153 Lys in GyrA (${\geq}4{\mu}g/ml$), Ser-91 Ile in ParC (${\geq}16{\mu}g/ml$), and Val-450 Phe (${\geq}64{\mu}g/ml$) in GyrB. These substitutions seem to have an impact on resistance to MF, and GyrB change was found only in the highest concentration and seems to be associated with high-level resistance to MF. This, as far as we know, is the first description of a relationship between MF resistance phenotype and genotype.
Keywords
Mycoplasma hominis; moxifloxacin; resistance; QRDRs; mutations;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Yoshida, H., M. Bogaki, M. Nakamura, L. M. Yamanaka, and S. Nakamura. 1991. Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob. Agents Chemother. 35, 1647-1650.   DOI   ScienceOn
2 Yoshida, H., M. Bogaki, M. Nakamura, and S. Nakamura. 1990. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob. Agents Chemother. 34, 1271-1272.
3 Gruson, D., S. Pereyre, H. Renaudin, A. Charron, C. Bebear, and C. M. Bebear. 2005. In vitro development of resistance to six and four fluoroquinolones in Mycoplasma pneumoniae and Mycoplasma hominis, respectively. Antimicrob. Agents Chemother. 49, 1190-1193.   DOI
4 Houssaye, S., L. Gutmann, and E. Varon. 2002. Topoisomerase mutations associated with in vitro selection of resistance to moxifloxacin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 46, 2712-2715.   DOI
5 Kenny, G. E., P. A. Young, F. D. Cartwright, K. E. Sjostrom, and W. M. Huang. 1999. Sparfloxacin selects gyrase mutations in first-step Mycoplasma hominis mutants, whereas ofloxacin selects topoisonmerase IV mutations. Antimicrob. Agents Chemother. 43, 2493-2496.
6 Kim, E. C., P. Charukamnoetkanok, A. M. Poothullil, B. Paton, and R. I. Pineda. 2005. Second, third, and fourth generation fluoroquinolone susceptibilities of methacillin resistant staph aureus (MRSA) cultures collected at the Massachusetts Eye and Ear Infirmary. Invest. Ophthalmol. Vis. Sci. 46, E-Abstract 2770.
7 Madoff, S. and D. C. Hooper. 1988. Nongenitourinary infections caused by Mycoplasma hominis in adults. Rev. Infect. Dis. 10, 602-613.   DOI
8 McMahon, D. K., J. S. Dummer, A. W. Pasculle, and G. H. Cassel. 1990. Extragenital Mycoplasma hominis infections in adults. Am. J. Med. 89, 275-281.   DOI
9 Pan, X. S., J. Ambler, S. Mehttar, and L. M. Fisher. 1996. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40, 2321-2326.
10 Pestova, E., J. J. Millichap, G. A. Noskin, and L. R. Peterson. 2000. Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones. J. Antimicrob. Chemother. 45, 583-590.   DOI
11 Pollack, J. D. 1992. Carbohydrate metabolism and energy conservation, In Maniloff, J., R. N. McElhaney, L. R. Finch, and J. B. Baseman (eds.), Mycoplasmas: Molecular biology and pathogenesis. pp. 181-200, American Society for Microbiology, Washington, D.C.
12 Bebear, C. M., H. Renaudin, A. Charron, M. Clerc, S. Pereyre, and C. Bebear. 2003. DNA gyrase and topoisomerase IV mutations in clinical isolates of Ureaplasma spp. and Mycoplasma hominis resistant to fluoroquinolones. Antimicrob. Agents Chemother. 47, 3323-3325.   DOI
13 Brenclaglia, M. I., P. Cipriani, and C. Mancini. 1975. Antimicrobial activity of aminoglycosides against clinical strains of Mycoplasma hominis. J. Antimicrob. Chemother. 1, 333-336.   DOI
14 Cassel, G. H. and K. B. Waites. 1989. Venereal mycoplasmal infections, In Hoeprich, P. D., and M. C. Jordan, (eds.), Infectious diseases, a modern treatise of infectious processes. J. B. Lippincott Company, Philadelphia.
15 Cassel, G. H. and K. B. Waites, and D. T. Crouse. 1991. Perinatal mycoplasmal infections. Clin. Perinatol. 18, 241-262
16 Cullen, M. E., A. W. Wyke, R. Kuroda, L. M. Fisher. 1989. Cloning and characterization of a DNA gyrase A gene from Escherichia coli that confers clinical resistance to 4-quinolones. Antimicrob. Agents Chemother. 33, 886-894.   DOI   ScienceOn
17 Drudy, D., T. Quinn, R. O'Mahony, L. Kyne, P. Ó'Gaora, and S. Fanning. 2006. High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile. Antimicrob. Agents Chemother. 58, 1264-1267.   DOI
18 Dybvig, K. and L. L. Voelker. 1996. Molecular biology of mycoplasmas. Annu. Rev. Microbiol. 50, 25-57.   DOI
19 Raherison, S., P. Gonzalez, H. Renaudin, A. Charron, C. Bebear, and C. M. Bebear. 2002. Evidence of active efflux in resistance to ciprofloxacin and to ethidium bromide by Mycoplasma hominis. Antimicrob. Agents Chemother. 46, 672-679.   DOI
20 Reece, R. and A. Maxwell. 1991. DNA gyrase: structure and function. Crit. Rev. Biochem. Mol. Biol. 26, 335-375.   DOI
21 Walkty, A., D. A. Boyd, D. Gravel, J. Hutchinson, A. McGeer, D. Moore, A. Simor, K. Suh, G. Taylor, M. Miller, and M. R. Mulvey. 2010. Molecular characterization of moxifloxacin resistance from Canadian Clostridium difficile clinical isolates. Diagn. Microbiol. Infect. Dis. 66, 419-424.   DOI